The company, whose technology won FDA Breakthrough Device designation earlier this year and which signed a deal with Philips earlier this month, plans to use the money to support FDA clearance and other efforts.
Investors such as Jim Breyer, Breyer Capital CEO, and Julian Robertson, who founded hedged fund Tiger Global Management, among other investors, led the round according to Fuchs.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.